BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35499695)

  • 21. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
    de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping of the functional anatomy of lymphatic drainage to the axilla in early breast cancer: A cohort study of 933 cases.
    Dorogi B; Bukovszky B; Mátrai T; Sávolt Á; Polgár C; Kelemen P; Kovács T; Rényi-Vámos F; Ivády G; Kovács E; Téglás M; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2019 Feb; 45(2):103-109. PubMed ID: 30322669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conservative axillary surgery is emerging in the surgical management of breast cancer.
    Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E; Haba Y
    Breast Cancer; 2023 Jan; 30(1):14-22. PubMed ID: 36342647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
    Riedel F; Heil J; Feisst M; Moderow M; von Au A; Domschke C; Michel L; Schaefgen B; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2020 Nov; 184(2):627-636. PubMed ID: 32816190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of survival outcomes between axillary conservation and axillary lymph node dissections in N1 early breast cancer: a propensity-matched SEER analysis.
    Wu N; Su X; Tan Q; Luo J; Yuan Y; Hou L; Li J
    Clin Transl Oncol; 2023 Apr; 25(4):1091-1101. PubMed ID: 36515887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer?
    Giuliano AE; Morrow M; Duggal S; Julian TB
    Clin Exp Metastasis; 2012 Oct; 29(7):687-92. PubMed ID: 22926446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-sentinel axillary tumor burden applying the ACOSOG Z0011 eligibility criteria to a large routine cohort.
    Riedel F; Heil J; Feißt M; Rezai M; Moderow M; Sohn C; Schütz F; Golatta M; Hennigs A
    Breast Cancer Res Treat; 2019 Sep; 177(2):457-467. PubMed ID: 31236814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial.
    Tseng J; Alban RF; Siegel E; Chung A; Giuliano AE; Amersi FF
    Breast J; 2021 Mar; 27(3):216-221. PubMed ID: 33586201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
    Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparing Early-Stage Breast Cancer Patients with Sentinel Lymph Node Metastasis with and without Completion Axillary Lymph Node Dissection: A Systematic Review and Meta-Analysis.
    Heiranizadeh N; Rafiei Shahamabadi M; Dehghan HR; Jafari-Nedooshan J; Kargar S; Zare M; Amooei A; Shiryazdi SM; Broomand MA; Moravej MT; Sadri Z
    Asian Pac J Cancer Prev; 2022 Aug; 23(8):2561-2571. PubMed ID: 36037108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
    Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
    Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
    Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
    Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative predictors of high and low axillary nodal burden in Z0011 eligible breast cancer patients with a positive lymph node needle biopsy result.
    Lim GH; Upadhyaya VS; Acosta HA; Lim JMA; Allen JC; Leong LCH
    Eur J Surg Oncol; 2018 Jul; 44(7):945-950. PubMed ID: 29705286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
    Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
    Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
    Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
    Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Which patients with sentinel node-positive breast cancer can avoid axillary dissection?
    Ho AY; Cody HS
    Am Soc Clin Oncol Educ Book; 2013; ():61-5. PubMed ID: 23714457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of T Stages on the Choice of Axillary Evaluation Modality in Breast Cancer Patients With 1-2 Sentinel Lymph Node Metastases.
    Liu D; Chang L; Zhao X; Dai L; Cui H; Liu P; Zhai Z; Wu H; Ma X; Kang H
    Clin Breast Cancer; 2024 Jun; 24(4):e232-e243.e1. PubMed ID: 38368246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
    Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
    Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.